caa a22 4500 477057942 CHVBK 20180405111352.0 cr unu---uuuuu 170330e19960301xx s 000 0 eng 10.1007/BF00195932 doi (NATIONALLICENCE)springer-10.1007/BF00195932 Improved pharmacodynamics of l -asparaginase-loaded in human red blood cells [Elektronische Daten] [R. Kravtzoff, C. Ropars, I. Desbois, M. Chassaigne, J. Lamagnere, Ph. Colombat, J. Muh, Ch. Valat] To evaluate the modification of pharmacodynamic parameters induced by the administration of l-asparaginase loaded into red blood cells, 13 patients received a single dose of l-asparaginase internalised into the carrier. The enzyme was loaded using a reversible lysis-resealing process. The dose per patient ranged from 30 to 200 IU·kg−1. Considerable heterogeneity occurred between patients: the level of l-asparaginase circulating after 24 h represented 47% of the total injected dose as compared to 74.8% for red blood cells (RBCs). However, the half-life of the enzyme remaining in the circulation was very similar to that of the RBC carrier, i.e. 29 days and 27 days, respectively, compared with 8-24 h for the free enzyme. Sustained elimination of plasma l-asparagine occurred, the duration of which was dependent on the injected dose. A single injection of 30·IU·kg−1 was sufficient to eliminate plasma l-asparagine over 10 days. With 150-200 IU·kg−1 the elimination period was extended to 50 days. These data show that the use of RBCs as carriers of l-asparaginase greatly improves the pharmacodynamic parameters of the drug. Springer-Verlag, 1996 Erythrocytes nationallicence l -Asparaginase nationallicence carrier nationallicence lysedresealed erythrocytes nationallicence pharmacodynamics nationallicence Kravtzoff R. Laboratoire de Biopharmacologie Transfusionnelle, INSERM U316, CRTS, BP 2009, F-37020, Tours, France aut Ropars C. Laboratoire de Biopharmacologie Transfusionnelle, INSERM U316, CRTS, BP 2009, F-37020, Tours, France aut Desbois I. Centre Régional de Transfusion Sanguine, Tours, France aut Chassaigne M. Centre Régional de Transfusion Sanguine, Tours, France aut Lamagnere J. Service Oncologie Médicale et Maladies du Sang, CHRU, Tours, France aut Colombat Ph Service Oncologie Médicale et Maladies du Sang, CHRU, Tours, France aut Muh J. Service de Biochimie, CHRU, Tours, France aut Valat Ch Service de Médecine Nucléaire, CHRU, Tours, France aut European Journal of Clinical Pharmacology Springer-Verlag 49/6(1996-03-01), 465-470 0031-6970 49:6<465 1996 49 228 https://doi.org/10.1007/BF00195932 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00195932 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kravtzoff R. Laboratoire de Biopharmacologie Transfusionnelle, INSERM U316, CRTS, BP 2009, F-37020, Tours, France aut NATIONALLICENCE 700 1- Ropars C. Laboratoire de Biopharmacologie Transfusionnelle, INSERM U316, CRTS, BP 2009, F-37020, Tours, France aut NATIONALLICENCE 700 1- Desbois I. Centre Régional de Transfusion Sanguine, Tours, France aut NATIONALLICENCE 700 1- Chassaigne M. Centre Régional de Transfusion Sanguine, Tours, France aut NATIONALLICENCE 700 1- Lamagnere J. Service Oncologie Médicale et Maladies du Sang, CHRU, Tours, France aut NATIONALLICENCE 700 1- Colombat Ph Service Oncologie Médicale et Maladies du Sang, CHRU, Tours, France aut NATIONALLICENCE 700 1- Muh J. Service de Biochimie, CHRU, Tours, France aut NATIONALLICENCE 700 1- Valat Ch Service de Médecine Nucléaire, CHRU, Tours, France aut NATIONALLICENCE 773 0- European Journal of Clinical Pharmacology Springer-Verlag 49/6(1996-03-01), 465-470 0031-6970 49:6<465 1996 49 228 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer